what is tirzepatide sodium (LY3298176) | GIP/GLP-1 Receptor Agonist | CAS 2023788-19-2 (free base) tirzepatide.pptx

Total Cost of Ownership: 24-Month Treatment Comparison (Complete Journey): Bottom Line on Costs: For most people paying cash or with high copays, compounded alternatives provide the same or similar medication at 67-81% lower costs than brand-name Mounjaro

Available data suggest the incidence may be somewhat higher at greater doses and during periods of dose escalation, though precise figures by dose group and comparison with placebo rates should be sought from the published trial data directly

Overall, the use of the GLP-1 receptor agonist-SGLT-2 inhibitor combination was associated with a 30% lower risk of MACE (7.0 v 10.3 per 1000 person years

These provide vitamins, minerals, and fiber in a way your body can use